Stocks To Watch on Analyst Actions: Revance Therapeutics Inc. (NASDAQ:RVNC), Brandywine Realty Trust (NYSE:BDN), Sodastream International Ltd. (NASDAQ:SODA)

Analysts at Janney Capital Markets have lowered their 2014 and 2015 earnings estimates for Chiquita Brands International Inc. (NYSE:CQB), while maintaining a neutral rating on the stock. The firm has lowered its 2014 EPS to $1.01 from $1.12, and reduced its 2015 EPS forecast to $1.25 from $1.29 a share.

The estimate adjustment comes just a few days after Chiquita Brands International Inc. (NYSE:CQB) reported Q4 2013 EPS that fell well below analyst estimates due to weak North American banana pricing as a result of bad weather. “While we like everything we’ve seen from management and this likely temporary cyclical weakness in banana,” said Janney, “fundamentals could prove a good chance to accumulate for the long-term.” Shares of Chiquita Brands International Inc. (NYSE:CQB) are steady in pre-market activity at $10.94, and move within a 52-week spread of $5.90 – $13.68.

Analysts at BMO Capital have initiated coverage of biopharmaceutical company Revance Therapeutics Inc. (NASDAQ:RVNC) with an Outperform rating. The firm set its price target on the stock at $37 a share. In the pre-market session, shares of Revance Therapeutics Inc. (NASDAQ:RVNC) are flat at $26.93, within a 52-week range of $21 – $31.

Real estate investment trust Brandywine Realty Trust (NYSE:BDN) has been upgraded by analysts at BMO Capital to an Outperform rating from Market Perform. The price target has been set at $16.50 a share. In pre-market trading, shares of Brandywine Realty Trust (NYSE:BDN) are unchanged at $14.65, and move within a 52-week range of $12.23 – $16.06.

Sodastream International Ltd. (NASDAQ:SODA) has been downgraded by analysts at Barclays to an equalweight rating from overweight. The firm also lowered its price target by more than a quarter to $40 from $55 a share. In the pre-market session, shares of Sodastream International Ltd. (NASDAQ:SODA) are down 2.43% to $38.52, within a 52-week range of $35.27 – $77.80.

Analysts at MP Securities have initiated coverage of pharmaceutical company Egalet Corp. (NASDAQ:EGLT) with a market outperform rating and a $19 price target. Shares of Egalet (NASDAQ:EGLT) are steady in the pre-market session at $12.87, and trade within a 52-week range of $11.82 – $13.67.



Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone